Calamos Advisors
ALXN

Calamos Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Calamos Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-61,000
Closed -$7.57M – 733
2018
Q2 		$7.57M Buy
+61,000
New +$7.13M 0.05% 359

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Calamos Advisors's ALXN Position: Q3 2021 in Review

Calamos Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 169,936 shares — an estimated $31.2M sold.

Calamos Advisors first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $99.8M in Q4 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Calamos Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Calamos Advisors sold 169,936 Alexion Pharmaceuticals shares in Q3 2021, an estimated $31.2M.
  • Calamos Advisors first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Calamos Advisors's Alexion Pharmaceuticals position peaked at $99.8M in Q4 2015.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Calamos Advisors's 13F filing for Q3 2021, filed 26 Oct 2021.